Pépin D, F Paradis, C Perez-Iratxeta, DJ Picketts and BC Vanderhyden (2013). The ISWI ATPase Snf2L is required for superovulation and regulates Fgl2 in differentiating mouse granulosa cells. Biol. Reprod. (in press) [Feb. 1; Epub ahead of print]
Gamwell LF, M Merziotis, K Gambaro, SL Arcand, V Snoulten, C Davis, JA Squire, DL Huntsman, PN Tonin and BC Vanderhyden (2013). Characterization of a small cell ovarian cancer cell line: Genomic anomalies and responsiveness to therapeutics. Orphanet Journal of Rare Diseases 8: 33.
King SM, SM Quartuccio SM, BC Vanderhyden and JE Burdette (2013). Early transformative changes in normal ovarian surface epithelium induced by oxidative stress require Akt upregulation, DNA damage, and epithelial-stromal interaction. Carcinogenesis 34: 1125-1133.
Lemay CG, JL Rintoul, A Kus, JM Paterson, V Garcia, TJ Falls, L Ferreira, BW Bridle, DP Conrad, VA Tang, JS Diallo, R Arulanandam, F Le Boeuf, K Garson, BC Vanderhyden, DF Stojdl, BD Lichty, HL Atkins, KA Parato, JC Bell and RC Auer (2012). Harnessing oncolytic virus-mediated anti-tumour immunity in an infected cell vaccine. Mol. Ther. 20: 1791-1799.
Garson K, Gamwell LF, E Pitre and BC Vanderhyden (2012). Technical challenges and limitations of current mouse models of ovarian cancer. J. Ovarian Res. 5: 39.
Gamwell LF, O Collins and BC Vanderhyden (2012). The mouse ovarian surface epithelium contains a population of LY6A (SCA-1) expressing progenitor cells that are regulated by ovulation-associated factors. Biol. Reprod. 87: 80.
Parato K, CJ Breitbach, F Le Boeuf, J Wang, C Storbeck, C Ilkow, JS Diallo, T Falls, J Burns, V Garcia, F Kanji, L Evgin, K Hu, F Paradis, S Knowles, TH Hwang, BC Vanderhyden, R. Auer, DH Kirn and JC Bell (2012). The oncolytic poxvirus JX-594 selectively replicates in and destroys cancer cells driven by genetic pathways commonly activated in cancers. Mol. Ther. 20: 749-758.
Pépin D, ZQ Shao, G Huppé, A Wakefield, CW Chu, Z Sharif and BC Vanderhyden (2011). Kallikreins 5, 6 and 10 differentially alter pathophysiology and overall survival in an ovarian cancer xenograft model. PLoS One. 6(11): e26075.
Laviolette LA, J-F Ethier, MK Senterman, PJ Devine and BC Vanderhyden (2011). Induction of a menopausal state alters the growth and histology of ovarian tumors in a mouse model of ovarian cancer. Menopause 18: 549-557.
Laviolette LA, K Garson, EA Macdonald, MK Senterman, K Courville, CA Crane and BC Vanderhyden. (2010). 17?-estradiol accelerates tumor onset and decreases survival in a transgenic mouse model of ovarian cancer. Endocrinology 151: 929-938.
Clark-Knowles KV, MK Senterman, O Collins and BC Vanderhyden (2009). Conditional inactivation of Brca1, p53, and Rb in mouse ovaries results in the development of leiomyosarcomas. PLoS ONE 4(12):e8534.
Nguyên TL-A, H Abdelbary, M Arguello, C Breitbach, S Leveille, J-S Diallo, A Yasmeen, TA Bismar, D Kirn, T Falls, VE Snoulten, BC Vanderhyden, J Werier, H Atkins, MJV Vähä-Koskela, DF Stojdl, JC Bell and J Hiscott (2008). Chemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysis. Proc. Nat. Acad. Sci. 105: 14981-14986.
Schilder RJ, MW Sill, RB Lee, TJ Shaw, MK Senterman, AJP Klein-Szanto, Z Miner and BC Vanderhyden (2008). A Phase II evaluation of imatinib methylate in the treatment of recurrent or persistent ovarian or primary peritoneal carcinoma. J. Clin. Onc. 26: 3418-3425.
Shaw TJ, EC Lacasse, JP Durkin and BC Vanderhyden (2008). Down-regulation of XIAP expression in ovarian cancer cells induces apoptosis in vitro and in vivo. Int. J. Cancer 122: 1430-1434.
Thomas FH, RS Ismail J-Y Jiang and BC Vanderhyden (2008). Kit ligand 2 promotes murine oocyte growth in vitro. Biol. Reprod. 78: 167-175.
Salehi F, LD Dunfield, KP Phillips, D Krewski and B Vanderhyden (2008). Risk factors for ovarian cancer: An overview with emphasis on hormonal factors. J.Toxicol. Environ. Health, Part B, 11: 301-321.
Shaw TJ and BC Vanderhyden (2007). AKT mediates the pro-survival effects of KIT in ovarian cancer cells and is a determinant of sensitivity to imatinib mesylate. Gynecol. Oncol. 105:122–131.
Clark-Knowles KV, K Garson, J Jonkers and BC Vanderhyden (2007). Conditional inactivation of Brca1 in the mouse ovarian surface epithelium results in an increase in preneoplastic changes. Exp. Cell Res. 313: 133-145.
Thomas FH and BC Vanderhyden (2007). Oocyte growth and developmental competence. In: In-vitro Maturation of Human Oocytes: From Basic Science to Clinical Application. SL Tan, RC Chiang and WM Buckett (Eds.). Informa Healthcare, Abingdon, UK, pp 1-14.
Pépin D, BC Vanderhyden, DJ Picketts and BD Murphy (2007). ISWI chromatin Remodeling in Ovarian Somatic and Germ Cells: Revenge of the NURFs. Trends Endocrinol. Metab. 18: 215-224.
Chambers AF and BC Vanderhyden (2006). Ovarian cancer biomarkers in urine. (Commentary). Clinical Cancer Research 12: 323-327.
Lazzaro MA, D Pépin, N Pescador, BD Murphy, BC Vanderhyden and DJ Picketts (2006). The ISWI protein SNF2L regulates steroidogenic acute regulatory protein (StAR) expression during terminal differentiation of ovarian granulosa cells. Mol. Endocrinol. 20: 2406-2417.
Thomas FH and BC Vanderhyden (2006). Oocyte-granulosa cell interactions during mouse follicular development: regulation of Kit ligand expression and its role in oocyte growth. Reprod. Biol. and Endocrinology, Apr 12; 4: 19.
Gilks CB, BC Vanderhyden, S Zhu, M van de Rijn, TA Longacre (2005). Distinction between serous tumors of low malignant potential and serous carcinomas based on global mRNA expression profiling. Gyn. Oncol. 96: 684-694
Vanderhyden BC (2005). Loss of ovarian function and the risk of ovarian cancer. Cell and Tissue Research. 322: 117-124.
Garson K, TJ Shaw, KV Clark, DS Yao and BC Vanderhyden (2005). Models of ovarian cancer—Are we there yet? Mol. Cell. Endocrinol. 239: 15-26.
Steller M, TJ Shaw, BC Vanderhyden and J-F Ethier (2005). Inhibin resistance is associated with aggressive tumorigenicity of ovarian cancer cells. Mol. Cancer Res. 3: 50-61.
Gittens JEI, KJ Barr, BC Vanderhyden and GM Kidder (2005). Interplay between paracrine signalling and gap junctional communication in ovarian follicles. J. Cell Sci. 118: 113-122.
Thomas FH, J-F Ethier, S Shimasaki and BC Vanderhyden (2005). Follicle-stimulating hormone regulates oocyte growth by modulation of expression of oocyte and granulosa cell factors. Endocrinology 146: 941-949.